Literature DB >> 25646469

Aberrant recombination and repair during immunoglobulin class switching in BRCA1-deficient human B cells.

Andrea Björkman1, Per Qvist2, Likun Du1, Margarita Bartish1, Apostolos Zaravinos1, Konstantinos Georgiou1, Anders D Børglum2, Richard A Gatti3, Therese Törngren4, Qiang Pan-Hammarström5.   

Abstract

Breast cancer type 1 susceptibility protein (BRCA1) has a multitude of functions that contribute to genome integrity and tumor suppression. Its participation in the repair of DNA double-strand breaks (DSBs) during homologous recombination (HR) is well recognized, whereas its involvement in the second major DSB repair pathway, nonhomologous end-joining (NHEJ), remains controversial. Here we have studied the role of BRCA1 in the repair of DSBs in switch (S) regions during immunoglobulin class switch recombination, a physiological, deletion/recombination process that relies on the classical NHEJ machinery. A shift to the use of microhomology-based, alternative end-joining (A-EJ) and increased frequencies of intra-S region deletions as well as insertions of inverted S sequences were observed at the recombination junctions amplified from BRCA1-deficient human B cells. Furthermore, increased use of long microhomologies was found at recombination junctions derived from E3 ubiquitin-protein ligase RNF168-deficient, Fanconi anemia group J protein (FACJ, BRIP1)-deficient, or DNA endonuclease RBBP8 (CtIP)-compromised cells, whereas an increased frequency of S-region inversions was observed in breast cancer type 2 susceptibility protein (BRCA2)-deficient cells. Thus, BRCA1, together with its interaction partners, seems to play an important role in repairing DSBs generated during class switch recombination by promoting the classical NHEJ pathway. This may not only provide a general mechanism underlying BRCA1's function in maintaining genome stability and tumor suppression but may also point to a previously unrecognized role of BRCA1 in B-cell lymphomagenesis.

Entities:  

Keywords:  B cells; BRCA1; alternative end-joining; immunoglobulin class switch recombination; nonhomologous end-joining

Mesh:

Substances:

Year:  2015        PMID: 25646469      PMCID: PMC4343177          DOI: 10.1073/pnas.1418947112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

1.  The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons.

Authors:  Laure Perrin-Vidoz; Olga M Sinilnikova; Dominique Stoppa-Lyonnet; Gilbert M Lenoir; Sylvie Mazoyer
Journal:  Hum Mol Genet       Date:  2002-11-01       Impact factor: 6.150

2.  BRCA1-mediated repression of mutagenic end-joining of DNA double-strand breaks requires complex formation with BACH1.

Authors:  Lisa Dohrn; Daniela Salles; Simone Y Siehler; Julia Kaufmann; Lisa Wiesmüller
Journal:  Biochem J       Date:  2012-02-01       Impact factor: 3.857

Review 3.  Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects.

Authors:  B Evers; J Jonkers
Journal:  Oncogene       Date:  2006-09-25       Impact factor: 9.867

Review 4.  BRCA1 and its toolbox for the maintenance of genome integrity.

Authors:  Michael S Y Huen; Shirley M H Sy; Junjie Chen
Journal:  Nat Rev Mol Cell Biol       Date:  2009-12-23       Impact factor: 94.444

5.  Alternative end-joining catalyzes robust IgH locus deletions and translocations in the combined absence of ligase 4 and Ku70.

Authors:  Cristian Boboila; Mila Jankovic; Catherine T Yan; Jing H Wang; Duane R Wesemann; Tingting Zhang; Alex Fazeli; Lauren Feldman; Andre Nussenzweig; Michel Nussenzweig; Frederick W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-25       Impact factor: 11.205

Review 6.  The AID-induced DNA damage response in chromatin.

Authors:  Jeremy A Daniel; André Nussenzweig
Journal:  Mol Cell       Date:  2013-05-09       Impact factor: 17.970

7.  Cancer suppression by the chromosome custodians, BRCA1 and BRCA2.

Authors:  Ashok R Venkitaraman
Journal:  Science       Date:  2014-03-28       Impact factor: 47.728

8.  53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.

Authors:  Peter Bouwman; Amal Aly; Jose M Escandell; Mark Pieterse; Jirina Bartkova; Hanneke van der Gulden; Sanne Hiddingh; Maria Thanasoula; Atul Kulkarni; Qifeng Yang; Bruce G Haffty; Johanna Tommiska; Carl Blomqvist; Ronny Drapkin; David J Adams; Heli Nevanlinna; Jiri Bartek; Madalena Tarsounas; Shridar Ganesan; Jos Jonkers
Journal:  Nat Struct Mol Biol       Date:  2010-05-09       Impact factor: 15.369

9.  Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients.

Authors:  Noel F C C de Miranda; Konstantinos Georgiou; Longyun Chen; Chenglin Wu; Zhibo Gao; Apostolos Zaravinos; Susana Lisboa; Gunilla Enblad; Manuel R Teixeira; Yixin Zeng; Roujun Peng; Qiang Pan-Hammarström
Journal:  Blood       Date:  2014-08-29       Impact factor: 22.113

10.  53BP1 is required for class switch recombination.

Authors:  Irene M Ward; Bernardo Reina-San-Martin; Alexandru Olaru; Kay Minn; Koji Tamada; Julie S Lau; Marilia Cascalho; Lieping Chen; Andre Nussenzweig; Ferenc Livak; Michel C Nussenzweig; Junjie Chen
Journal:  J Cell Biol       Date:  2004-05-24       Impact factor: 10.539

View more
  4 in total

1.  Protection of nascent DNA at stalled replication forks is mediated by phosphorylation of RIF1 intrinsically disordered region.

Authors:  Sandhya Balasubramanian; Matteo Andreani; Júlia Goncalves Andrade; Tannishtha Saha; Devakumar Sundaravinayagam; Javier Garzón; Wenzhu Zhang; Oliver Popp; Shin-Ichiro Hiraga; Ali Rahjouei; Daniel B Rosen; Philipp Mertins; Brian T Chait; Anne D Donaldson; Michela Di Virgilio
Journal:  Elife       Date:  2022-04-13       Impact factor: 8.713

Review 2.  Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Authors:  David D Bowtell; Steffen Böhm; Ahmed A Ahmed; Paul-Joseph Aspuria; Robert C Bast; Valerie Beral; Jonathan S Berek; Michael J Birrer; Sarah Blagden; Michael A Bookman; James D Brenton; Katherine B Chiappinelli; Filipe Correia Martins; George Coukos; Ronny Drapkin; Richard Edmondson; Christina Fotopoulou; Hani Gabra; Jérôme Galon; Charlie Gourley; Valerie Heong; David G Huntsman; Marcin Iwanicki; Beth Y Karlan; Allyson Kaye; Ernst Lengyel; Douglas A Levine; Karen H Lu; Iain A McNeish; Usha Menon; Steven A Narod; Brad H Nelson; Kenneth P Nephew; Paul Pharoah; Daniel J Powell; Pilar Ramos; Iris L Romero; Clare L Scott; Anil K Sood; Euan A Stronach; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

3.  An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.

Authors:  Ewa Przybytkowski; Thomas Davis; Abdelrahman Hosny; Julia Eismann; Ursula A Matulonis; Gerburg M Wulf; Sheida Nabavi
Journal:  BMC Cancer       Date:  2020-03-12       Impact factor: 4.430

4.  Loss of ZBTB24 impairs nonhomologous end-joining and class-switch recombination in patients with ICF syndrome.

Authors:  Angela Helfricht; Peter E Thijssen; Magdalena B Rother; Rashmi G Shah; Likun Du; Sanami Takada; Mélanie Rogier; Jacques Moritz; Hanna IJspeert; Chantal Stoepker; Monique M van Ostaijen-Ten Dam; Vincent Heyer; Martijn S Luijsterburg; Anton de Groot; Rianca Jak; Gwendolynn Grootaers; Jun Wang; Pooja Rao; Alfred C O Vertegaal; Maarten J D van Tol; Qiang Pan-Hammarström; Bernardo Reina-San-Martin; Girish M Shah; Mirjam van der Burg; Silvère M van der Maarel; Haico van Attikum
Journal:  J Exp Med       Date:  2020-11-02       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.